Del Frisco's Restaurant Group Inc. (DFRG) Jumps 5.43% on December 28

Equities Staff |

Del Frisco's Restaurant Group Inc. (DFRG) was among the biggest gainers on the Russell 2000 for Monday December 28 as the stock popped 5.43% to $15.54, representing a gain of $0.8 per share. Some 454,514 shares traded hands on 2,948 trades, compared with an average daily volume of 295,934 shares out of a total float of 23.31 million. The stock opened at $15.11 and traded with an intraday range of $15.91 to $15.04.

After today's gains, Del Frisco's Restaurant Group Inc. reached a market cap of $362.19 million. Del Frisco's Restaurant Group Inc. has had a trading range between $25.95 and $12.25 over the last year, and it had a 50-day SMA of $14.08 and a 200-day SMA of $16.55.

The stock has a P/E Ratio of 25.4.

Del Frisco's Restaurant Group Inc develops, owns and operates contemporary restaurants.

Del Frisco's Restaurant Group Inc. is based out of Southlake, TX and has some 4,745 employees. Its CEO is Mark S. Mednansky.

For a complete fundamental analysis analysis of Del Frisco's Restaurant Group Inc., check out’s Stock Valuation Analysis report for DFRG. To see the latest independent stock recommendations from’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Emerging Growth

Immunovaccine Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.

Private Markets


Airbnb is a community marketplace for people to list, discover, and book unique accommodations around the world — online or from a mobile phone. Whether an apartment for a night,…


Lyft matches drivers using their own personal vehicles with passengers who request rides through the smartphone app, and the passengers pay automatically through the app. When using Lyft, passengers have…